Boehringer Ingelheim's sales growth in 2018 hit by increasing price pressure on Spiriva

Headline results for 2018:

Prescription drug sales

12.6 billion euros ($14.3 billion)

-0.5%

Revenue

17.5 billion euros ($19.8 billion)

-3%

Profit

2.1 billion euros ($2.4 billion)

Versus loss of 223 million euros ($252 million)

Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

"In 2018, the return on net sales increased from 19.3 to 19.8 percent, while our equity ratio rose from nearly 38 percent to 40 percent. Thus we are also a very healthy company from a financial point of view," remarked Michael Schmelmer, member of the board responsible for finance.

Other results:

  • Spiriva: 2.4 billion euros ($2.7 billion), down 15 percent, hit by increasing price pressure
  • Jardiance: 1.5 billion euros ($1.7 billion), up 45 percent
  • Pradaxa: 1.5 billion euros ($1.7 billion), up 3 percent
  • Trajenta: 1.4 billion euros ($1.6 billion), up 5 percent
  • Ofev: 1.1 billion euros ($1.2 billion), up 28.7 percent on a currency-adjusted basis
  • Biopharmaceutical contract manufacturing: 734 million euros ($830 million), up 8.3 percent

Looking ahead:

Boehringer Ingelheim expects "slight" growth in net sales this year.

To read more Top Story articles, click here.